237 related articles for article (PubMed ID: 27168098)
1. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies.
Tonk ECM; Gurwitz D; Maitland-van der Zee AH; Janssens ACJW
Pharmacogenomics J; 2017 Jul; 17(4):386-392. PubMed ID: 27168098
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of drug hypersensitivity.
Phillips EJ; Mallal SA
Pharmacogenomics; 2010 Jul; 11(7):973-87. PubMed ID: 20602616
[TBL] [Abstract][Full Text] [Related]
3. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
Lucas A; Nolan D; Mallal S
J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
[TBL] [Abstract][Full Text] [Related]
4. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
Roses AD
Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
[TBL] [Abstract][Full Text] [Related]
5. [Prospective validation of a pharmacogenetic test: the PREDICT-1 study].
Muñoz de Benito RM; Arribas López JR
Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():40-4. PubMed ID: 18680695
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics: The right drug for you.
Drew L
Nature; 2016 Sep; 537(7619):S60-2. PubMed ID: 27602742
[No Abstract] [Full Text] [Related]
7. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.
Nolan D
Crit Rev Clin Lab Sci; 2009; 46(3):153-65. PubMed ID: 19514905
[TBL] [Abstract][Full Text] [Related]
8. The contribution of pharmacogenetics to pharmacovigilance.
Bondon-Guitton E; Despas F; Becquemont L
Therapie; 2016 Apr; 71(2):223-8. PubMed ID: 27080842
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics testing for type B adverse drug reactions to anti-infective drugs: the example of hypersensitivity to abacavir.
Agundez JA; Esguevillas G; Amo G; Garcia-Martin E
Recent Pat Antiinfect Drug Discov; 2014; 9(2):151. PubMed ID: 25891395
[No Abstract] [Full Text] [Related]
10. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?
Phillips EJ
Clin Infect Dis; 2006 Jul; 43(1):103-5. PubMed ID: 16758425
[No Abstract] [Full Text] [Related]
11. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
[TBL] [Abstract][Full Text] [Related]
12. Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.
Hughes AR; Brothers CH; Mosteller M; Spreen WR; Burns DK
Pharmacogenomics; 2009 Feb; 10(2):225-33. PubMed ID: 19207023
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01.
Sousa-Pinto B; Pinto-Ramos J; Correia C; Gonçalves-Costa G; Gomes L; Gil-Mata S; Araújo L; Delgado L
J Allergy Clin Immunol; 2015 Oct; 136(4):1092-4.e3. PubMed ID: 25934581
[No Abstract] [Full Text] [Related]
14. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.
Nelson MR; Bacanu SA; Mosteller M; Li L; Bowman CE; Roses AD; Lai EH; Ehm MG
Pharmacogenomics J; 2009 Feb; 9(1):23-33. PubMed ID: 18301416
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE
AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465
[TBL] [Abstract][Full Text] [Related]
16. Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01.
Cascella R; Strafella C; Ragazzo M; Zampatti S; Borgiani P; Gambardella S; Pirazzoli A; Novelli G; Giardina E
Pharmacogenomics J; 2015 Apr; 15(2):196-200. PubMed ID: 25201286
[TBL] [Abstract][Full Text] [Related]
17. Abacavir pharmacogenetics--from initial reports to standard of care.
Martin MA; Kroetz DL
Pharmacotherapy; 2013 Jul; 33(7):765-75. PubMed ID: 23649914
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.
Cargnin S; Jommi C; Canonico PL; Genazzani AA; Terrazzino S
Pharmacogenomics; 2014 May; 15(7):963-76. PubMed ID: 24956250
[TBL] [Abstract][Full Text] [Related]
19. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events.
Hughes S; Hughes A; Brothers C; Spreen W; Thorborn D;
Pharm Stat; 2008; 7(2):121-9. PubMed ID: 17534855
[TBL] [Abstract][Full Text] [Related]
20. HLA-associated drug hypersensitivity and the prediction of adverse drug reactions.
Negrini S; Becquemont L
Pharmacogenomics; 2017 Oct; 18(15):1441-1457. PubMed ID: 29017379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
